A Langley man with a rare type of kidney disease is suing the provincial government, saying it took too long to approve his treatment with a new type of drug.

Paul Chung is suing the province, saying it violated his charter rights to 香蕉视频直播渓ife, liberty, and security of the person.香蕉视频直播�

Chung was in his first year of university in August of 2017 when he was was diagnosed with atypical hemolytic uremic syndrome (aHUS), which causes blood clots in small blood vessels. That can lead to stroke, heart attack, kidney failure, and death.

In his notice of civil claim, filed with the B.C. Supreme Court registry on July 3, Chung said he is now permanently on kidney dialysis because the provincial government waited until November 2017 to approve his treatment with a new drug, Soliris, 香蕉视频直播渁 very expensive drug capable of curing or materially improving his serious blood disorder,香蕉视频直播� he sited in the suit.

READ MORE:

After he was turned down, Chung waged a public campaign to convince the government to cover the cost of the new drug treatment.

By the time the province approved a three-month trial, the Chung claim stated, he was suffering from internal bleeding that required surgery.

香蕉视频直播淭he decision was too little, too late for the plaintiff [Chung] as Soliris must be administered promptly after diagnosis to be effective.香蕉视频直播�

During that time, the lawsuit maintains that other B.C. patients with the same condition recovered because they were given Soliris within four to eight weeks of their first diagnosis.

Chung remains on dialysis, unable to work or attend school, the claim stated.

Denying Chung coverage was, under the circumstances, 香蕉视频直播済rossly disproportionate and unreasonable under any public interest calculus,香蕉视频直播� the lawsuit stated.

Langley Advance Times has reached out to the provincial government and Chung for comment.

香蕉视频直播� Stay tuned for more香蕉视频直播�

_________________________________

Is there more to this story?

Email: dan.ferguson@langleyadvancetimes.com

Like us on or follow us on

_________________________________